Učitavanje...

Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective

Lenalidomide, a novel immunomodulatory agent, was approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome and relapsed multiple myeloma. Data from preclinical studies paved the way for clinical trials of lenalidomide in mantle cell lymphoma (MCL). Initial phase...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Desai, Madhav, Newberry, Kate, Ou, Zhishuo, Wang, Michael, Zhang, Liang
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2014
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4031905/
https://ncbi.nlm.nih.gov/pubmed/24883181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620714532124
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!